SKF 83566 hydrobromide

Pricing Availability   Qty
Description: Potent and selective D1-like antagonist; also inhibits adenylyl cyclase 2
Chemical Name: 8-Bromo-2,3,4,5-tetrahydro-3-methyl-5-phenyl-1H-3-benzazepin-7-ol hydrobromide
Purity: ≥98% (HPLC)
Datasheet
Citations (10)
Reviews
Literature (4)

Biological Activity for SKF 83566 hydrobromide

SKF 83566 hydrobromide is a potent and selective D1-like dopamine receptor antagonist (Ki~ 0.56 nM for D1; KB = 2 μM for D2). Also antagonist at the vascular 5-HT2 receptor (Ki = 11 nM). Displays selective inhibition of adenylyl cyclase 2 (AC2); inactive against AC1 or AC5. Centrally active following systemic administration in vivo.

Compound Libraries for SKF 83566 hydrobromide

SKF 83566 hydrobromide is also offered as part of the Tocriscreen 2.0 Max. Find out more about compound libraries available from Tocris.

Technical Data for SKF 83566 hydrobromide

M. Wt 413.15
Formula C17H18BrNO.HBr
Storage Desiccate at RT
Purity ≥98% (HPLC)
CAS Number 108179-91-5
PubChem ID 23581817
InChI Key SDQJYYGODYRPBR-UHFFFAOYSA-N
Smiles Br.CN1CCC2=CC(Br)=C(O)C=C2C(C1)C1=CC=CC=C1

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data for SKF 83566 hydrobromide

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
water 2.07 5 with gentle warming
DMSO 41.31 100

Preparing Stock Solutions for SKF 83566 hydrobromide

The following data is based on the product molecular weight 413.15. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 2.42 mL 12.1 mL 24.2 mL
5 mM 0.48 mL 2.42 mL 4.84 mL
10 mM 0.24 mL 1.21 mL 2.42 mL
50 mM 0.05 mL 0.24 mL 0.48 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

Product Datasheets for SKF 83566 hydrobromide

Certificate of Analysis / Product Datasheet
Select another batch:

References for SKF 83566 hydrobromide

References are publications that support the biological activity of the product.

Fritts et al (1998) Locomotor stereotypy produced by dexbenzetimide and scopol. is reduced by SKF 83566, not sulpiride. Pharmacol.Biochem.Behav. 60 639 PMID: 9678647

Meyer et al (1993) Effects of DA D1 antagonists SCH23390 and SK&F83566 on locomotor activities in rats. Pharmacol.Biochem.Behav. 44 429 PMID: 8446676

Ohlstein and Berkowitz (1985) SCH 23390 and SK&F 83566 are antagonists at vascular DA and serotonin receptors. Eur.J.Pharmacol. 108 205 PMID: 3884345

Conley et al (2013) Development of a high-throughput screening paradigm for the discovery of small-molecule modulators of adenylyl cyclase: identification of an adenylyl cyclase 2 inhibitor. J.Pharmacol.Exp.Ther. 347 276 PMID: 24008337


If you know of a relevant reference for SKF 83566 hydrobromide, please let us know.

View Related Products by Product Action

View all D1 and D5 Receptor Antagonists

Keywords: SKF 83566 hydrobromide, SKF 83566 hydrobromide supplier, Potent, selective, D1-like, antagonists, Dopamine, Receptors, D5, dopaminergic, SKF83566, hydrobromide, D1, and, Adenylyl, Cyclase, 1586, Tocris Bioscience

10 Citations for SKF 83566 hydrobromide

Citations are publications that use Tocris products. Selected citations for SKF 83566 hydrobromide include:

Huang et al (2014) D1/D5 receptors and histone deacetylation mediate the Gateway Effect of LTP in hippocampal dentate gyrus. Learn Mem 21 153 PMID: 24549570

Stramiello (2008) D1/5 receptor-mediated enhancement of LTP requires PKA, Src family kinases, and NR2B-containing NMDARs. Neuropharmacology 55 871 PMID: 18644393

Liu et al (2008) Increased DA level enhances male-male courtship in Drosophila. World J Gastroenterol 28 5539 PMID: 18495888

Belinsky et al (2013) DA receptors in human embryonic stem cell neurodifferentiation. Stem Cells Dev 22 1522 PMID: 23286225


Do you know of a great paper that uses SKF 83566 hydrobromide from Tocris? Please let us know.

Reviews for SKF 83566 hydrobromide

There are currently no reviews for this product. Be the first to review SKF 83566 hydrobromide and earn rewards!

Have you used SKF 83566 hydrobromide?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Dopamine Receptors Scientific Review

Dopamine Receptors Scientific Review

Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.

Addiction Poster

Addiction Poster

The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.

Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.